Clinical Trial: Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT and SPIKEVAX X Injection

U.S., March 27 -- ClinicalTrials.gov registry received information related to the study (NCT06333704) titled 'Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT and SPIKEVAX X Injection' on March 20.

Brief Summary: The main objective of the surveillance is to evaluate the incidence of the adverse events (AEs), and other safety related information in South-Korean population.

Study Type: Observational

Condition: SARS-CoV-2

Intervention: * Biological: SPIKEVAX Bivalent

No study drug will be administered during this study as this is an observational study.

Other Names:

SPIKEVAX Bivalent BA.1

SPIKEVAX BIVALENT BA.4/5

SARS-CoV-2-mRNA vaccine

* Biological: SPIKEVAX X

No study drug will be administered durin...